Allarity Therapeutics Secures First Commercial Agreement Under CLIA Services Strategy
The agreement complements revenue from standard gene expression and DRP services. The supplied body is truncated before further details.
Story updates
11:46:43 AM UTC
SquawkNews
Agreement complements revenue from standard gene expression and DRP® services- Development and validation services will support a European biotechnology company’s precision oncology predictive device for use in the United States- Strategy expands commercial use of existing laboratory capabilities…